NEW YORK (
CHANGE IN RATINGS
upgraded at Sterne Agee to Buy. $27 price target. Estimates also boosted, as new management initiatives should drive growth.
upgraded at Goldman from Sell to Neutral, Goldman Sachs said. Valuation call, as the stock is down 49% over the past year. $3.50 price target.
upgraded at UBS from Neutral to Buy, UBS said. $96 price target. Expect better near-term clinical data.
upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. $26 price target. Expect continued strong clinical data in the near term.
downgraded at UBS from Buy to Neutral, UBS said. $156 price target. Valuation call, as the stock is up 56% from the last upgrade.
rated new Neutral at JPMorgan. $37 price target. Lagging fundamentals balance cash generation story.
Brocade Communications Systems
upgraded to buy at TheStreet Ratings.
downgraded to hold at TheStreet Ratings.
downgraded at UBS from Buy to Neutral, UBS said. $80 price target. Valuation call, as the stock is up 27% since Revlimid was not approved in the EU.
downgraded at Goldman from Buy to Neutral, Goldman Sachs said. $39 price target. Estimates also cut, given lower expected iron ore prices and rising costs.
upgraded at JPMorgan to Overweight from Neutral, JPMorgan said. $70 price target. Sustainable growth in materials.
upgraded at JP Morgan from Underweight to Neutral, JP Morgan said. Valuation call.
downgraded at Jefferies to Hold from Buy, Jefferies said. $35 price target. Full valuation.
downgraded at Citigroup from Neutral to Sell, Citigroup said. $31 price target. Estimates also cut, given higher expected costs.
Fifth Third Bancorp
downgraded at Oppenheimer to Perform from Outperform, Oppenheimer said. Catalyst achieved.
upgraded at Sterne Agee to Buy from Hold, Sterne Agee said. $11.50 price target. Attractive valuation.
downgraded at JP Morgan from Overweight to Neutral, JP Morgan said. Stock is already factoring in a late-stage economic recovery.
downgraded at Deutsche from Buy to Hold, Deutsche Bank said. $39 price target. Stock is already pricing in a potential price hike, which may not yet materialize.
upgraded at Lazard to Buy from Neutral, Lazard said. $52 price target. Company is leveraged to high debt issuance rates.
upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Stock is attractive, following the recent rotation out of utility stocks.
upgraded at Goldman from Neutral to Buy, Goldman Sachs said. $25 price target. Texas should drive growth and the company generates solid free cash flow.
downgraded at Goldman from Buy to Hold, Goldman Sachs said. $34 price target. Valuation call, as the sector has made a strong move over the past several weeks.
PNC Financial Services Group
upgraded at Oppenheimer to Outperform from Perform, Oppenheimer said. $75 price target. Acquisition of RBC Bank (USA) is an ideal platform.
upgraded at Jefferies to Buy from Hold, Jefferies said. $135 price target. Taking the right steps.
downgraded at Deutsche from Buy to Hold, Deutsche Bank said. Valuation call, based on a $75 price target.
upgraded at Nomura from Neutral to Buy, Nomura said. $7 price target. Company is cutting costs and fears of increased competition have been overblown.
rated new Overweight at JPMorgan. $19 price target. Cheap on legacy FCF with upside.
rated new Market Perform at Leerink. Uncertainty surrounds Relistor and the company lacks near-term catalysts.
downgraded at Sterne Agee from Buy to Neutral, Sterne Agee said. Valuation call, as the stock is up 31% year-to-date.
downgraded at JP Morgan from Overweight to Neutral, JP Morgan said. Valuation call.
STOCK COMMENTS / EPS CHANGES
target raised at Oppenheimer. Shares of AIRM now seen reaching $130, Oppenheimer said. Bullish following meetings with management. Outperform rating.
numbers cut at Credit Suisse. Shares of CLH now seen reaching $65. Estimates also reduced, given lower expected oil service margins. Outperform rating.
added to US 1 List at BofA/Merrill. ENDP was placed on the US 1 list, Bank of America/Merrill Lynch said. Opana ER market share should soon recover. Buy rating and $40 price target.
numbers raised at Jefferies. Shares of FMC now seen reaching $66, Jefferies said. Estimates also raised on greater emphasis on organic growth. Buy rating.
estimates, target reduced at JMP. INTC estimates were cut through 2013, JMP Securities said. Company lowered its guidance. Outperform rating and new $30 price target.
estimates, target raised at Nomura. Shares of LULU now seen reaching $62, according to Nomura. Estimates also increased, as the company is realizing a lower tax rate. Neutral rating.
added to Conviction Buy List at Goldman. Company can continue to cut costs to right-size the business.
added to US 1 List at BofA/Merrill. Comp sales growth should continue to turn around. Buy rating and $45 price target.
cut from Conviction Buy List at Goldman. Valuation call.
numbers increased at Citi. WSM estimates were raised through 2014, Citigroup said. Expect higher back-to-school sales. Buy rating and new $49 price target.
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on
This article was written by a staff member of TheStreet.